Last reviewed · How we verify
A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 35299 in different formulations, compared to Daivonex® ointment and Daivonex® ointment vehicle, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
Details
| Lead sponsor | LEO Pharma |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 24 |
| Start date | 2012-04 |
| Completion | 2012-06 |
Conditions
- Psoriasis Vulgaris
Interventions
- B LEO 35299 20 mg/g cream
- C LEO 35299 20 mg/g cream
- E LEO 35299 10 mg/g solution
- F LEO 35299 10 mg/g solution
- Daivonex® ointment
- Daivonex® ointment vehicle
Primary outcomes
- Change in the Total Clinical Score From Baseline to Day 22 — Baseline to Day 22
Investigator's rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinical Score. Total Clinical Score range from 0 (all symptoms absent) to 9 (all symptoms severe)
Countries
France